Companies Dominating the Polycythemia Vera Treatment Landscape
- Thermo Fisher Scientific Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pfizer Inc.
- Galena Biopharma
- Bristol-Myers Squibb Company
- Novartis AG
- Eli Lilly and Company
- PharmaEssentia Corporation
- Bayer AG
- Viatris Inc.
- Teva Pharmaceuticals Industries Ltd
Browse Key Market Insights with Data Illustration:
In the News
- PharmaEssentia Corporation, a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver novel hematology and oncology biologics, has announced reported that the first patients are now receiving treatment from ECLIPSE PV, a phase 3b clinical study evaluating an accelerated dosing regimen for cordeginterferon alfa. -2b-njft uses a prefilled syringe to treat polycythemia vera (PV) in adults.
- In November 2021, the US Food and Drug Administration approved Besrem injection for adults with polycythemia vera, a blood disorder that causes overproduction of red blood cells. The extra cells thicken the blood, slowing blood flow and increasing the chance of blood clots.
